- Home
- PLUR vs BLRX Comparison
PLUR vs BLRX Comparison
Compare PLUR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | BLRX |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 11.7M |
| IPO Year | 2026 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PLUR | BLRX |
|---|---|---|
| Price | $0.95 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.6K | 12.9K |
| Earning Date | 11-11-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,016,000.00 | N/A |
| Revenue This Year | $902.46 | $37.33 |
| Revenue Next Year | N/A | $37.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $2.11 |
| 52 Week High | $4.87 | $4.07 |
Technical Indicators
Market Signals| Indicator | PLUR | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 28.94 |
| Support Level | $0.90 | N/A |
| Resistance Level | $1.85 | $2.56 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.43 | 11.00 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.